OTCMKTS:PHGUF

Pharming Group - PHGUF Stock Forecast, Price & News

$1.03

0.00 (0.00%)

(As of 03/21/2023 12:00 AM ET)

Add

Compare

Today's Range: $1.03
▼
$1.03
50-Day Range: $0.97
▼
$1.45
52-Week Range: $0.74
▼
$1.45

Volume: N/A
Average Volume: 337 shs
Market Capitalization: $671.98 million

P/E Ratio: 25.76
Dividend Yield: N/A
Price Target: N/A

About Pharming Group (OTCMKTS:PHGUF) Stock

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.

Receive PHGUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter.

PHGUF Stock News Headlines

March 17, 2023 | americanbankingnews.com

Pharming Group (OTCMKTS:PHGUF) and LifeVantage (NASDAQ:LFVN) Critical Analysis

March 13, 2023 | finance.yahoo.com

Pharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank in light of US Government announcement

March 21, 2023 | Press Reach (Ad)

Stock Market Update

This stock is taking America by storm. Find out why it's trending right now.

February 28, 2023 | finanznachrichten.de

Pharming Group N.V.: Notice of Full Year 2022 financial results

February 28, 2023 | finance.yahoo.com

Notice of Full Year 2022 financial results

February 21, 2023 | finanznachrichten.de

Pharming Group N.V.: Pharming announces first patient enrolled in pediatric clinical trial of leniolisib

January 9, 2023 | finance.yahoo.com

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 49% Above Its Share Price

December 19, 2022 | finance.yahoo.com

Pharming Group N.V.'s (AMS:PHARM) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

March 21, 2023 | Press Reach (Ad)

Stock Market Update

This stock is taking America by storm. Find out why it's trending right now.

December 15, 2022 | finance.yahoo.com

Pharming Highlights Interim Data From Rare Immune Deficiency Study

December 15, 2022 | finance.yahoo.com

Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

November 23, 2022 | finance.yahoo.com

Recent Price Trend in Pharming Group N.V. Sponsored ADR (PHAR) is Your Friend, Here's Why

October 31, 2022 | finance.yahoo.com

Pharming Group N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

October 29, 2022 | seekingalpha.com

Pharming Group N.V. (PHGUF) Q3 2022 Earnings Call Transcript

October 12, 2022 | finance.yahoo.com

Pharming Group Notice of Q3 Results

October 11, 2022 | finance.yahoo.com

Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib

October 6, 2022 | finance.yahoo.com

Pharming's Leniolisib Goes Under Priority FDA Review For Rare Immune System Disorder

September 14, 2022 | reuters.com

Pharming Group NV

August 6, 2022 | seekingalpha.com

Pharming Group N.V. 2022 Q2 - Results - Earnings Call Presentation

August 4, 2022 | finance.yahoo.com

Pharming Group reports financial results for the first half of 2022

August 2, 2022 | msn.com

EMA committee grants accelerated assessment for Pharming Group’s leniolisib

July 19, 2022 | morningstar.com

Pharming Group - Stock Quote PHGUF

June 2, 2022 | finance.yahoo.com

Pharming Group to present at Jefferies Healthcare Conference 2022

May 4, 2022 | finance.yahoo.com

Pharming receives agreement of Paediatric Investigation Plan and Promising Innovative Medicine designation for leniolisib from UK MHRA

January 6, 2022 | finanznachrichten.de

Pharming Group N.V.: Pharming receives positive EMA decision on paediatric investigation plan (PIP) for leniolisib in Europe

January 6, 2022 | finance.yahoo.com

Pharming receives positive EMA decision on paediatric investigation plan (PIP) for leniolisib in Europe

October 28, 2021 | finance.yahoo.com

Pharming Group NV (PHGUF) to Report Q3 Results: What Awaits?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PHGUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter.

PHGUF Company Calendar

Last Earnings: 3/05/2015
Today: 3/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:PHGUF
Previous Symbol: OTC:PHGUF
CUSIP: N/A
CIK: N/A
Web: www.pharming.com
Phone: (171) 524-7400
Fax: 31-0-71-524-7445
Employees: 277
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $0.04
Trailing P/E Ratio: 25.76
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $16 million
Net Margins: 14.90%
Pretax Margin: N/A
Return on Equity: 15.52%
Return on Assets: 7.77%

Debt

Debt-to-Equity Ratio: 0.68
Current Ratio: 5.40
Quick Ratio: 4.68

Sales & Book Value

Annual Sales: $198.87 million
Price / Sales: 3.38
Cash Flow: $0.06 per share
Price / Cash Flow: 16.96
Book Value: $0.31 per share
Price / Book: 3.32

Miscellaneous

Outstanding Shares: 652,410,000
Free Float: N/A
Market Cap: $671.98 million
Optionable: Not Optionable
Beta: 1.10

Key Executives

Sijmen de Vries
Chief Executive Officer & Executive Director

Mireille Sanders
Chief Operations Officer

Jeroen Henk Wakkerman
Chief Financial Officer

Robert Friesen
Chief Scientific Officer

Anurag Relan
Chief Medical Officer

Key Competitors

View All Competitors

PHGUF Stock - Frequently Asked Questions

How have PHGUF shares performed in 2023?: Pharming Group's stock was trading at $1.1499 at the start of the year. Since then, PHGUF shares have decreased by 10.4% and is now trading at $1.03.
View the best growth stocks for 2023 here.
Are investors shorting Pharming Group?: Pharming Group saw a decline in short interest during the month of February. As of February 28th, there was short interest totaling 2,709,800 shares, a decline of 16.4% from the February 13th total of 3,240,100 shares. Based on an average trading volume of 400 shares, the short-interest ratio is currently 6,774.5 days.
View Pharming Group's Short Interest.
How were Pharming Group's earnings last quarter?: Pharming Group (OTCMKTS:PHGUF) released its quarterly earnings results on Thursday, March, 5th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.01. Pharming Group had a trailing twelve-month return on equity of 15.52% and a net margin of 14.90%.
What is Pharming Group's stock symbol?: Pharming Group trades on the OTCMKTS under the ticker symbol "PHGUF."

How do I buy shares of Pharming Group?: Shares of PHGUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Pharming Group's stock price today?: One share of PHGUF stock can currently be purchased for approximately $1.03.
How much money does Pharming Group make?: Pharming Group (OTCMKTS:PHGUF) has a market capitalization of $671.98 million and generates $198.87 million in revenue each year. The biotechnology company earns $16 million in net income (profit) each year or $0.04 on an earnings per share basis.
How many employees does Pharming Group have?: The company employs 277 workers across the globe.
How can I contact Pharming Group?: Pharming Group's mailing address is Darwinweg 24, Leiden P7, 2333 CR. The official website for the company is www.pharming.com. The biotechnology company can be reached via phone at (171) 524-7400, via email at investor@pharming.com, or via fax at 31-0-71-524-7445.

This page (OTCMKTS:PHGUF) was last updated on 3/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial